ライフサイエンスコーパス: myosin light chain

1 ownstream effectors (phospholipase Cbeta and myosin light chain).

2 ction and lower expression of phosphorylated myosin light chain.

3 he activation of RhoA and phosphorylation of myosin light chain.

4 cells to injured cardiomyocytes (expressing myosin light chain.

5 in light chain phosphatase and subsequently, myosin light chain.

6 ting Rho kinase activity and phosphorylating myosin light chain.

7 including glycogen synthase kinase-3beta and myosin light chain.

8 um as judged by increased phosphorylation of myosin light chain.

9 e substrates via reduction of phosphorylated myosin light chain.

10 Myosin light chain 1 (LC1) was labeled with a fluorescen

11 repression of troponin T3, troponin I2, and myosin light chain 1 between cardiac and slow-twitch ske

12 the actin-tropomyosin and myosin heavy chain-myosin light chain 1 interactions independently correlat

13 ns of OGA with alpha-actin, tropomyosin, and myosin light chain 1, along with reduced OGT and increas

14 3-kDa IgE-reactive protein was identified as myosin light chain 1, designated Gallus domesticus 7 (Ga

15 itoylation of proteins involved in motility (myosin light chain 1, myosin A), cell morphology (PhIL1)

16 l muscle genes troponin T3, troponin I2, and myosin light chain 1.

17 ked actin-tropomyosin and myosin heavy chain-myosin light chain 1.

18 gin: including myofibrillar proteins (titin, myosin light chain 1/3, myomesin 3 and filamin-C), glyco

19 Species-specific peptides derived from myosin light chain-1 and 2 were identified for authentic

20 of troponin I, troponin T, phospholamban, or myosin light chain-1 or -2.

21 Myosin light chain 2 ( MYL2) gene encodes the myosin reg

22 tractility is enhanced by phosphorylation of myosin light chain 2 (MLC2) by cardiac-specific MLC kina

23 ly the phosphorylation of the ROCK substrate myosin light chain 2 (MLC2) in intact human breast, lung

24 for PKM2's localization and interaction with myosin light chain 2 (MLC2) in the contractile ring regi

25 Endogenous PP1cbeta, myosin light chain 2 (MLC2), and myosin IIA heavy chain

26 rin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2).

27 Because phosphorylation of cardiac myosin light chain 2 (MLC2v), bound to myosin at the hea

28 ted kinase (ROCK) signaling concomitant with myosin light chain 2 and MYPT phosphorylation.

29 ction and permeability via the Rho-dependent myosin light chain 2 and vascular endothelial (VE)-cadhe

30 d pulmonary acetylcholine and phosphorylated myosin light chain 2 in bronchial smooth muscles.

31 s whereas the phosphorylation of ventricular myosin light chain 2 was significantly increased, implyi

32 signaling and by the localization of phospho-myosin light chain 2, in turn controlling the changes in

33 xtracellular signal-regulated kinase, and/or myosin light chain 2.

34 decreased phosphorylation of the regulatory myosin light chain-2 (MLC2), a critical cytoskeletal reg

35 by myosin regulatory proteins (for example, myosin light chain-2 [MLC2]) in cardiac muscle remain po

36 osphorylation of several proteins, including myosin light chain-2 slow and troponin T and carbonylati

37 Since myosin light chain 20 (MLC(20)) phosphorylation appears

38 antly decreased in MetSyn lymphatic vessels, myosin light chain 20, MLC(20) phosphorylation was incre

39 In addition, increased phosphorylation of myosin light chain-20, a key regulator of lymphatic musc

40 ctural proteins myosin heavy chain alpha and myosin light chain 2a in real-time during early differen

41 ssion of cardiac alpha-actinin, connexin 43, myosin light chain 2a, alpha/beta-myosin heavy chain, an

42 Here we investigate one of these proteins, myosin light chain 4 (MYL4), which is important for cont

43 abnormal phenotypes in both models of MYL4 (myosin light chain 4)-related atrial cardiomyopathy.

44 sion, evidenced by reduced expression of the myosin light chain 9 (MYL9) component of myosin II compl

45 Independent of the myosin light chain activation, RHGF-1 acted through Rho-

46 ion, which prevents dephosphorylation of the myosin light chain, allowing actomyosin contractility to

47 increased levels of F-actin, phosphorylated myosin light chain, alpha-smooth muscle actin, collagen-

48 y, which is necessary for phosphorylation of myosin light chain and actin myosin-mediated contraction

49 wever, the structural features of this novel myosin light chain and its interaction with its cognate

50 activity to downstream effectors, including myosin light chain and p38(MAPK), and is reversed upon t

51 rease in permeability via phosphorylation of myosin light chain and subsequent shrinkage of human bra

52 by means of reducing the phosphorylation of myosin light chain and vascular endothelial (VE)-cadheri

53 he myofilament proteins, myosin heavy chain, myosin light chains and subunits of the Troponin complex

54 he R403Q myosin mutation, phosphorylation of myosin light chains, and an increased ADP:ATP ratio, des

55 Myosin light chains are key regulators of class 1 myosin

56 Pm and Azi-iso identified myosin, actin, and myosin light chain as targets of the anesthetics.

57 hereas F-actin, vinculin, and phosphorylated myosin light chain associated only with the peripheral a

58 Thr853 (pT853), CPI-17 at Thr38 (pT38), and myosin light chain at Ser19 (pS19).

59 ronger and more sustained phosphorylation of myosin light chain at serine 19 and threonine 18.

60 ion resulted in decreased phosphorylation of myosin light chains, attenuated smooth muscle contractil

61 A single lobe light chain, myosin light chain C (MlcC), was recently identified and

62 adjacent to the MTIP-binding site, and both myosin light chains co-located to the glideosome.

63 Phosphorylated myosin light chain colocalization with actin stress fibe

64 ing inflammation, and reduced phosphorylated myosin light chain concentration.

65 e, the complex included GAP40, an additional myosin light chain designated essential light chain (ELC

66 Apically, in the absence of CFL1 myosin light chain does not become phosphorylated, indic

67 structure of a phosphorylated smooth-muscle myosin light chain domain (LCD).

68 the 2.3-A-resolution crystal structure of a myosin light chain domain, corresponding to one type fou

69 e with the force-transducing rotation of the myosin light-chain domain.

70 pomethylation was also found in promoters of myosin light chain, dystrophin, actin polymerization, PA

71 ble-green-fluorescent-protein (PAGFP)-tagged myosin light chain expressed in zebrafish skeletal muscl

72 s p.Glu11Lys mutation in the atrial-specific myosin light chain gene MYL4.

73 alpha-smooth muscle actin and phosphorylated myosin light chain in cortical patches, decreased abunda

74 Interestingly, tropomyosin and myosin light chains in comminuted sausages were exclusiv

75 Those same doses of CXCL12 locked myosin light chain into a phosphorylated state, thereby

76 -actin and myosin accumulate and the ectopic myosin light chain is phosphorylated.

77 site to 0.45 mol of phosphate/mol by cardiac myosin light chain kinase (cMLCK) increases Ca(2+) sensi

78 tro and in vivo, the precise role of cardiac myosin light chain kinase (cMLCK), the primary kinase ac

79 he well-known, muscle-specific smooth muscle myosin light chain kinase (MLCK) (smMLCK) and skeletal m

80 on of myosin regulatory light chain (RLC) by myosin light chain kinase (MLCK) and myosin binding prot

81 thway involving the MAP kinases MEK and ERK, myosin light chain kinase (MLCK) and Myosin IIB.

82 ve activities of Ca(2+)-calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

83 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

84 in (RLC) phosphorylation, which is driven by myosin light chain kinase (MLCK) and Rho-associated kina

85 Here we have identified myosin light chain kinase (MLCK) as a regulator of membr

86 Inhibition of myosin light chain kinase (MLCK) blocked the effects of

87 testinal TJ permeability and the increase in myosin light chain kinase (MLCK) expression, confirming

88 ion phenotype was primarily due to increased myosin light chain kinase (MLCK) expression.

89 transgenic mice expressing calmodulin sensor myosin light chain kinase (MLCK) in smooth muscles, the

90 mplex (ARPC) subunit 2, 3, and 5, as well as myosin light chain kinase (MLCK) in these cells.

91 ocusing on regulatory roles of IFN-gamma and myosin light chain kinase (MLCK) in TW myosin phosphoryl

92 d in the absence or presence of the specific myosin light chain kinase (MLCK) inhibitor ML-7 under bo

93 ABSTRACT: Ca(2+) /calmodulin activation of myosin light chain kinase (MLCK) initiates myosin regula

94 Myosin light chain kinase (MLCK) is a key effector of ba

95 Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) phosphorylates smooth m

96 Herein, we show that myosin light chain kinase (MLCK) plays a central role in

97 , where it bound to its binding motif on the myosin light chain kinase (MLCK) promoter region, leadin

98 ulin-dependent protein kinase II (CaMKII) to myosin light chain kinase (MLCK) to myosin light chain,

99 myosin II, Rho-associated kinase (ROCK), and myosin light chain kinase (MLCK) were also recruited to

100 ted by arp2/3 and contractility regulated by myosin light chain kinase (MLCK) were responsible for th

101 The mylk1 gene encodes a 220-kDa nonmuscle myosin light chain kinase (MLCK), a 130-kDa smooth muscl

102 reduction in the expression and activity of myosin light chain kinase (MLCK), a primary regulator of

103 lity pathway involving Rho kinase (ROCK) and myosin light chain kinase (MLCK), culminating in the act

104 Myosin light chain kinase (MLCK)-dependent phosphorylati

105 erijunctional actomyosin ring contributes to myosin light chain kinase (MLCK)-dependent tight junctio

106 We showed previously that a myosin light chain kinase (MLCK)-myosin II pathway was r

107 ad spectrum of downstream targets, including myosin light chain kinase (MLCK).

108 ing EV trafficking, leading to activation of myosin light chain kinase (MLCK).

109 ght junction (TJ) permeability by activating myosin light chain kinase (MLCK; official name MYLK3) ge

110 sequencing, we found homozygous variants in myosin light chain kinase (MYLK) in both families.

111 d by TRPC6, in turn, activates the nonmuscle myosin light chain kinase (MYLK), which not only increas

112 nied by an increase in protein expression of myosin light chain kinase (P<0.05) and casein kinase II-

113 Smooth muscle myosin light chain kinase (SM-MLCK) is the key enzyme re

114 Smooth muscle myosin light chain kinase (smMLCK) is a calcium-calmodul

115 Smooth muscle myosin light chain kinase (smMLCK) is a member of a dive

116 ene that encodes nonmuscle and smooth muscle myosin light chain kinase (smMLCK) isoforms and regulate

117 riation in a gene of major effect, Stretchin Myosin light chain kinase (Strn-Mlck), which we validate

118 In turn, IL-1beta increased NF-kappaB and myosin light chain kinase activation in intestinal epith

119 osphorylated by Ca(2+) /calmodulin-dependent myosin light chain kinase and dephosphorylated by myosin

120 development in ileal smooth muscle depend on myosin light chain kinase and MLCP activities without ch

121 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase and myosin light chain phospha

122 Myosin light chain kinase and phosphatase activities are

123 Both myosin light chain kinase and Rho-associated kinase acte

124 lated through two myosin-signaling pathways, myosin light chain kinase and Rho-associated kinase.

125 lated these recombinant species with cardiac myosin light chain kinase and zipper-interacting protein

126 measuring the stabilization of calmodulin by myosin light chain kinase at dramatically higher unfoldi

127 Intestinal myosin light chain kinase expression decreased in Cd14-d

128 lly expressed gene (Speg) is a member of the myosin light chain kinase family.

129 osphorylated by a dedicated Ca(2+)-dependent myosin light chain kinase in fast skeletal muscle, where

130 nges, as determined by increased activity of myosin light chain kinase in the cytoplasm and enhanced

131 inant negative mutant RhoA(T19N) and Rho and myosin light chain kinase inhibitors.

132 The myosin light chain kinase long (MYLK-L) isoform is canon

133 he recent identification of cardiac-specific myosin light chain kinase necessary for basal RLC phosph

134 ression of contraction through inhibition of myosin light chain kinase normalized the effects of subs

135 ented cytoskeletal defects, while inhibiting myosin light chain kinase or phosphorylation of focal ad

136 We reveal that the calcium-calmodulin-myosin light chain kinase pathway controls sheath contra

137 hidden and unphosphorylated; on activation, myosin light chain kinase phosphorylates the monophospho

138 inal extension (Dmlc2(Delta2-46)), disrupted myosin light chain kinase phosphorylation sites (Dmlc2(S

139 We tested the functionality of myosin light chain kinase pseudogene (MYLKP1) in human c

140 rough RhoA GTPase, Rho-associated kinase, or myosin light chain kinase restored stiffness-dependent s

141 Phosphorylation of myosin-bound RLC by myosin light chain kinase substantially inhibits binding

142 m1a), expressed specifically in the MHB, and myosin light chain kinase together mediate MHBC cell len

143 ntraction with isoproterenol, or by blocking myosin light chain kinase with ML-7.

144 nhibition of actin polymerization as well as myosin light chain kinase with the drug ML7 limited both

145 RT-PCR analysis of tight junction proteins, myosin light chain kinase, and proinflammatory cytokine

146 density and progressed independently of Rac, myosin light chain kinase, and Rho kinase, suggesting a

147 including methionine sulfoxide reductase A, myosin light chain kinase, and Runt-related transcriptio

148 in action, including Mal2, Akap12, gelsolin, myosin light chain kinase, annexin-2, and Hsp70, manifes

149 ts the CaM binding domain of skeletal muscle myosin light chain kinase, forms a complex with CaM in t

150 in), regulators of the contractile response (myosin light chain kinase, myosin phosphatase target sub

151 ytosis, and localized phosphorylation of the myosin light chain kinase, thereby impinging on the acto

152 titutively active mutants of RhoA GTPase and myosin light chain kinase, we show that varying the expr

153 Upon photodisruption and recoil, myosin light chain kinase-dependent SFs located along th

154 nase- and myosin II motor-dependent (but not myosin light chain kinase-dependent) epithelial barrier

155 rge molecule permeability but did not affect myosin light chain kinase-induced increases in epithelia

156 at neutrophil transmigration is regulated by myosin light chain kinase-mediated endothelial cell cont

157 on by blocking the nuclear factor-kappaB and myosin light chain kinase-mediated redistribution of the

158 )) at Ser(19) by Ca(2+)/calmodulin-dependent myosin light chain kinase.

159 mplitude and partly by a mechanism involving myosin light chain kinase.

160 sphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(s) playe

161 Myosin light-chain kinase (MLCK) is a downstream target

162 egulated the downstream nuclear factor-B and myosin light-chain kinase (MLCK) signalling, and these c

163 Nonmuscle myosin light-chain kinase (nmMLCK), the predominant MLCK

164 mbers, we demonstrated the role of nonmuscle myosin light-chain kinase (nmMYLK) in Tat(1)(-)(7)(2) (1

165 ecifically, of myosin ATPase, Rho kinase, or myosin light-chain kinase activity).

166 contraction of actin filaments by activating myosin light-chain kinase and myosin II behind the leadi

167 Nonmuscle myosin light-chain kinase contributes to atherosclerosis

168 Here we identify a myosin light-chain kinase MRCK-1 as a key regulator of C

169 s, including phosphatidylinositol 3-kinases, myosin light-chain kinase, Ras-related C3 botulinum toxi

170 ofibrotic myofibroblast functions, including myosin light-chain kinase-mediated myofibroblast contrac

171 um channels and calcium/calmodulin-dependent myosin light-chain kinase.

172 in II heavy chain (MHC) and the long form of myosin light-chain kinase.

173 Here, we show that deletion of myosin light-chain kinases (MLCK) in the smooth muscle c

174 ibited reduced phosphorylation of regulatory myosin light chains known to activate this ATPase.

175 yosins that lack a tail region, the atypical myosin light chains may fulfill that role.

176 h increased JNK2 phosphorylation and reduced myosin light chain (MLC(20) ) phosphorylation.

177 IPF, using phosphorylation of the regulatory myosin light chain (MLC(20)) as a biomarker of in vivo c

178 nd CXCR4, and inhibited Ca(2+) mobilization, myosin light chain (MLC) 2 phosphorylation, and contract

179 ), which modifies the activity of regulatory myosin light chain (MLC) and cofilin by altering their p

180 ive manner and suppressed phosphorylation of myosin light chain (MLC) and CPI-17, but not myosin targ

181 hearts exhibited reduced phosphorylation of myosin light chain (MLC) and focal adhesion kinase (FAK)

182 phosphorylation of intracellular epithelial myosin light chain (MLC) and screened using Caco-2 monol

183 we demonstrate that the non-muscle ~214-kDa myosin light chain (MLC) kinase (nmMLCK) modulates the i

184 part, to a Ca(2+)-independent activation of myosin light chain (MLC) phosphatase by protein kinase G

185 Myosin light chain (MLC) phosphorylation and MLC kinase

186 Time- and dose-dependent myosin light chain (MLC) phosphorylation in response to

187 increased smooth muscle stress and decreased myosin light chain (MLC) phosphorylation in vivo, provid

188 of MRP4 expression on cAMP and cGMP levels, myosin light chain (MLC) phosphorylation, actin filament

189 nges in gene expression, actin cytoskeleton, myosin light chain (MLC) phosphorylation, and extracellu

190 uced MLCK1 recruitment as well as downstream myosin light chain (MLC) phosphorylation, barrier loss,

191 Barrier function, MAPk and myosin light chain (MLC) phosphorylation, tight junction

192 gonist-evoked intracellular calcium flux and myosin light chain (MLC) phosphorylation, which are prer

193 ell (VSMC) tone is regulated by the state of myosin light chain (MLC) phosphorylation, which is in tu

194 ROCK inhibition increased myosin light chain (MLC) phosphorylation, which is known

195 mulus requires phosphorylation of the 20 kDa myosin light chain (MLC), which activates crossbridge cy

196 RhoA-bound ROCK1 phosphorylates myosin light chain (MLC), which is required for actin-my

197 ough their effects on the phosphorylation of myosin light chain (MLC).

198 accompanied by diminished phosphorylation of myosin light chain (MLC).

199 pended on the phosphorylation of endothelial myosin light chain (MLC).

200 endothelial permeability by phosphorylating myosin light chain (MLC-P).

201 r calcium ([Ca(2+)]i) and phosphorylation of myosin light chains (MLC).

202 hoA and RhoC activity, which in turn affects myosin light-chain (MLC) phosphorylation.

203 esponsible for phosphorylation of regulatory myosin light chain (MLC20), resulting in actin-myosin cr

204 n several cytoskeletal/contractile proteins (myosin light chain MLY2, myosin heavy chain 6, myosin-bi

205 Myosin light chain (MYL1 and MYL3) showed high oxidative

206 increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representati

207 target subunit (MYPT1) and the expression of myosin light chain of myosin II (MLC2), which was identi

208 d RhoA/Rho kinase-induced phosphorylation of myosin light chain on Ser19.

209 et subunit of myosin phosphatase with either myosin light chain or HDAC6, a microtubule deacetylase.

210 ssociated with changes in phosphorylation of myosin light chain or of myosin light chain phosphatase

211 bsequent dephosphorylation for relaxation by myosin light chain phosphatase (MLCP) containing regulat

212 ctivation, force and phosphorylation of RLC, myosin light chain phosphatase (MLCP) targeting subunit

213 ulin-dependent myosin light chain kinase and myosin light chain phosphatase (MLCP), which contains a

214 l of phosphate/mol of RLC with inhibition of myosin light chain phosphatase (MLCP).

215 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

216 n light chain kinase and dephosphorylated by myosin light chain phosphatase (MLCP).

217 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

218 CPI-17, but not myosin targeting subunit of myosin light chain phosphatase (MYPT1).

219 ads to down-regulation of smooth muscle (SM) myosin light chain phosphatase activity, an increase in

220 Ca(2+) sensitivity usually is attributed to myosin light chain phosphatase activity, but findings in

221 the Rho signaling pathway and inhibition of myosin light chain phosphatase activity.

222 t phosphorylation of LC20 upon inhibition of myosin light chain phosphatase activity.

223 lated, phosphorylation of the ROCK substrate myosin light chain phosphatase and subsequently, myosin

224 through RhoA/ROCK-mediated inhibition of the myosin light chain phosphatase complex (MLCP).

225 unts of free Ca(2+)/calmodulin combined with myosin light chain phosphatase inhibition is sufficient

226 Inhibition of myosin light chain phosphatase leads to Ca(2+)-independe

227 nist-induced contractile force, RLC(20), and myosin light chain phosphatase phosphorylation in both i

228 Phosphorylation of the myosin light chain phosphatase regulatory subunit MYPT1

229 phosphorylation of myosin light chain or of myosin light chain phosphatase regulatory subunit.

230 by a GST-MYPT1(654-880) fragment inhibiting myosin light chain phosphatase were antagonized by the a

231 endogenous MYPT1 (the regulatory subunit of myosin light chain phosphatase) at Thr-696/Thr-853 or ac

232 hibitory protein of 17 kDa (CPI-17) inhibits myosin light chain phosphatase, altering the levels of m

233 This occurs through inhibition of myosin light chain phosphatase, leading to increased pho

234 eral different downstream substrates such as myosin light chain phosphatase, LIM kinase and ezrin/rad

235 vesicle biogenesis through the regulation of myosin light chain phosphatase.

236 The small phosphoprotein pCPI-17 inhibits myosin light-chain phosphatase (MLCP).

237 and/or the leucine zipper (LZ) domain of the myosin light-chain phosphatase component, myosin-binding

238 lex and allow reevaluation of the role(s) of myosin light-chain phosphatase partner polypeptides in r

239 [p.Cys157Arg]) affecting the same residue of myosin light chain, phosphorylatable, fast skeletal musc

240 etion of either RhoC or MRK causes sustained myosin light chain phosphorylation after LPA stimulation

241 he RhoA/Rho kinase pathway via inhibition of myosin light chain phosphorylation and actin depolymeriz

242 Force development, but not myosin light chain phosphorylation and actin polymerizat

243 ht chain phosphatase, altering the levels of myosin light chain phosphorylation and Ca(2+) sensitivit

244 ls regulate blood-brain barrier function via myosin light chain phosphorylation and increase in perme

245 s of connexin-50, together with decreases in myosin light chain phosphorylation and the levels of 14-

246 cells was accompanied by RhoA activation and myosin light chain phosphorylation and was reduced by th

247 RhoA activity and myosin light chain phosphorylation are elevated in GRAF3

248 Nevertheless, myosin light chain phosphorylation at Ser-19 and actin p

249 smooth muscle contraction without affecting myosin light chain phosphorylation at Ser-19.

250 increased migration was associated with high myosin light chain phosphorylation by PI3K/ERK-dependent

251 active Rho, localization of both RhoGTP and myosin light chain phosphorylation corresponds to Myo9b-

252 ractility, RhoA activation, and constitutive myosin light chain phosphorylation ex vivo compared with

253 ther, overexpression of HIF-1alpha decreased myosin light chain phosphorylation in HIF-1alpha-null SM

254 se of RhoA activity accompanied by augmented myosin light chain phosphorylation in mesenteric arterie

255 diminished Ca(2+)-independent and -dependent myosin light chain phosphorylation otherwise increased b

256 ellular calcium measurements, and regulatory myosin light chain phosphorylation status.

257 Increased myosin light chain phosphorylation suggested that noncan

258 ay activates phospholipase Cbeta and induces myosin light chain phosphorylation to enhance actomyosin

259 However, myosin light chain phosphorylation was not affected by T

260 Moreover, myosin light chain phosphorylation, a determinant of SMC

261 is required for cell spreading on collagen, myosin light chain phosphorylation, and focal adhesion m

262 Enhanced TW myosin light chain phosphorylation, arc formation, and b

263 companied by inhibition of RhoA activity and myosin light chain phosphorylation, as well as decreased

264 lcium, and decreased actin stress fibers and myosin light chain phosphorylation, without detectable c

265 tudies showed that nmMLCK acted through both myosin light chain phosphorylation-coupled and -uncouple

266 on in response to ACh, but it did not affect myosin light chain phosphorylation.

267 ion, activation of MRK causes a reduction in myosin light chain phosphorylation.

268 uction driven by stronger and more sustained myosin light chain phosphorylation.

269 ns low pulmonary vascular tone by decreasing myosin light chain phosphorylation.

270 ast, as expected, depletion of RhoA inhibits myosin light chain phosphorylation.

271 caused a decrease in actin stress fibers and myosin light chain phosphorylation.

272 he effect of Efnb1 on VSMC contractility and myosin light chain phosphorylation.

273 apical nonmuscle myosin II accumulation and myosin light chain phosphorylation.

274 oA, reduced RhoA GTP-loading and reversal of myosin light chain phosphorylation.

275 due to alterations in calcium homeostasis or myosin light chain phosphorylation.

276 phosphorylation at Ser-56 without affecting myosin light chain phosphorylation.

277 lowing cholinergic stimulation and increased myosin light chain phosphorylation.

278 1.38 +/- 0.072-fold (mean+/-SE) increase in myosin light-chain phosphorylation 48 h post-treatment,

279 PPAP2B inhibition resulted in myosin light-chain phosphorylation and intercellular gap

280 hat the Net1A isoform predominantly controls myosin light-chain phosphorylation and is required for t

281 ding via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin

282 When myosin light-chain phosphorylation was restored to norma

283 ivity via decreased intestinal smooth muscle myosin light-chain phosphorylation, leading to slower in

284 eously decreases PC relaxation by increasing myosin light-chain phosphorylation.

285 n also attenuated edema-induced decreases in myosin light-chain phosphorylation.

286 Confocal images of phospho-myosin light chain (pMLC) immunofluorescence, moreover,

287 d that active RhoA and ROCK effector phospho-myosin light chain (pMLC) were downregulated in endothel

288 ects PIP5K1C90 and subsequent phosphorylated myosin light chain polarization, and this polarization s

289 nuclear reprogramming of the muscle-specific myosin light chain promoter did occur.

290 raction force microscopy, and phosphorylated myosin light chain quantity and actin fiber colocalizati

291 uired for fusion as the expression of mutant myosin light chain reduced membrane fusion.

292 Contractile components (SM-actin and myosin light chain), regulators of the contractile respo

293 t chain phosphatase activity, an increase in myosin light chain (RLC(20)) phosphorylation and force.

294 , invertebrate tropomyosin, arginine kinase, myosin light chain, sarcoplasmic calcium-binding protein

295 e inhibition studies also implicated several myosin light chain sequences located near HC796-835 as p

296 MKII) to myosin light chain kinase (MLCK) to myosin light chain, the last of which controls the contr

297 Both filamentous actin and phosphorylated myosin light chain were enriched at the apical surface o

298 ted contraction (via ROCK phosphorylation of myosin light chain), which are coupled to ECM signaling

299 f Rho kinase activity and phosphorylation of myosin light chain, which induces airway smooth muscle c

300 evels and lower expression of phosphorylated myosin light chain, which is essential for vascular smoo